ClinConnect ClinConnect Logo
Search / Trial NCT06888232

Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients

Launched by MUHAMMAD AAMIR LATIF · Mar 15, 2025

Trial Information

Current as of April 26, 2025

Completed

Keywords

ClinConnect Summary

Given the significant burden of transfusion dependency, an effective and safe inducer is needed that could improve quality of life and reduce the healthcare costs associated with frequent transfusions and iron chelation therapy. If this study could establish the safety of thalidomide in terms of teratogenicity along with its efficacy, it would be a great support to multi-transfused thalassemic children.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Children of both genders
  • Aged 2-5 years
  • With transfusion-dependent thalassemia (TDT)
  • Whose parents/guardians showed willingness to adhere to follow-up visits
  • Exclusion Criteria:
  • Children with uncontrolled infections
  • Significant hepatic or renal dysfunction
  • Malignancy
  • Known contraindications to thalidomide

About Muhammad Aamir Latif

Muhammad Aamir Latif is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a background in clinical research and a focus on innovative therapeutic solutions, he collaborates with healthcare professionals and institutions to design, implement, and oversee clinical trials. His expertise encompasses various therapeutic areas, ensuring adherence to regulatory standards and ethical guidelines. Through strategic partnerships and a patient-centered approach, Muhammad Aamir Latif aims to contribute significantly to the development of safe and effective treatments, fostering advancements in healthcare and enhancing the quality of life for patients worldwide.

Locations

Multan, Punjab, Pakistan

Patients applied

0 patients applied

Trial Officials

Muhammad Aslam, FCPS

Principal Investigator

Children's Hospital and institute of Child Health Multan, Punjab, Pakistan

Sara Rubab, FCPS

Principal Investigator

Children's Hospital and institute of Child Health Multan, Punjab, Pakistan

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported